Blood · 2023 · 28 citations · 17 references
MedicineOncologyPharmacologyCancer ImmunologyImmunotherapyTumor ImmunologyB Cell BiologyCancer ImmunotherapyLymphoid NeoplasmsLymphoid TissueLymphoid TumorsCausal Subgroup AnalysisExploratory Subgroup AnalysisLymphoma Pathogenesis
ABSTRACT: Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab efficacy.
17
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis et al. · Nature · 2000 · 10K citations
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis, Vu N. Ngo, Georg Lenz et al. · Nature · 2010 · 1.6K citations · Full text
Medicine, Hematology, Oncology +14